835. Ibrutinib-associated bleeding: pathogenesis, management adn risk reduction strategies 848. Long-term treatment of cancer-associated Thrombosis: the choice of the optimal anticoagulant 858. I…
1541. C-reative protein gene polymorphism preditct the risk of thromboboembolic stroke in patiens with atrial fibrillation a more than 10-year prospective follow-up study 1547. Assement of clinica…
1728. Minimal factor XIII activity level to prevent major spontaneous bleeds 1737. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in…
1901. Qualification of a select one stage activated partial thromboplastin time based clotting assay and two chromogenic assays and two chromogenic assays for the post administration 1913. Effect …
2115. Effect of late prophylaxis in hemophilia on joint status a randomized trial 2125. Reversal of apixaban anticoagulation by four factor prothombin complex concetrates in healthy subjects a ran…
1241. Novel insight into the regulation of coagulation by factor V isoforms, tissue factors V isoforms tissue factor pathway inhibitor and protein s 1251. Diagnosis of acute pulmonary embolism 12…
1055. Incidence of intracranial bleeds in new users of low-dose aspirin a cohort study using the health improvement 1065. Predictive performance of the CHA2DS2 VASc rule in atrial fibrillation a …
1443. Balancing risk and benefit in venous thromboembolism trials concept for a bivariate endpoint trial design and analytic approach 1449. Hemophillia A and hemopholia B focus on arthropathy and …
2092. Prognostic role of embolic burden assessed at computed tomography angiography in patients with acute pulmonary embolism systematic review and meta analysis 2103. Pulmonary embolism severity …
1683. Benefits and challenges of going abroad for research or clinical training 1685. Protamine (heparin) induced trombocytopenia 1696. Current and future perspectives in imaging of venous 171…